141 related articles for article (PubMed ID: 28578773)
1. [The economic burden of cancer and the access to innovation should boost the use of real world data].
Thierry JP
Bull Cancer; 2017 Jun; 104(6):495-496. PubMed ID: 28578773
[No Abstract] [Full Text] [Related]
2. [Economic evaluation in oncology].
Schöffski O
Med Klin (Munich); 2000 Jun; 95 Suppl 1():14-7. PubMed ID: 10941248
[TBL] [Abstract][Full Text] [Related]
3. The reality of economics for oncologists.
Taylor D
Breast; 2017 Jun; 33():183-190. PubMed ID: 28432979
[TBL] [Abstract][Full Text] [Related]
4. Health economics in the Journal of Clinical Oncology and an evaluation of the indirect costs and benefits associated with adjuvant trastuzumab.
de Lima Lopes G; Gluck S
J Clin Oncol; 2007 Aug; 25(22):3382-3; author reply 3383. PubMed ID: 17664490
[No Abstract] [Full Text] [Related]
5. Many new cancer drugs in the United Kingdom are facing negative NICE rulings.
Low E;
J Clin Oncol; 2007 Jun; 25(18):2635-6; author reply 2637-8. PubMed ID: 17577049
[No Abstract] [Full Text] [Related]
6. Managing oncology costs.
Reeder CE; Gordon D
Am J Manag Care; 2006 Feb; 12(1 Suppl):S3-16; quiz S17-9. PubMed ID: 16478368
[TBL] [Abstract][Full Text] [Related]
7. This is a call to oncologists for action.
Micó C; Berrocal A; Blasco A; Caballero C; Iranzo V; Lobo M; Camps C
Clin Transl Oncol; 2018 Dec; 20(12):1493-1501. PubMed ID: 29796999
[TBL] [Abstract][Full Text] [Related]
8. Bending the cost curve in cancer care.
Good M; Good CB
N Engl J Med; 2011 Aug; 365(7):674-5; author reply 675-6. PubMed ID: 21848478
[No Abstract] [Full Text] [Related]
9. Perspectives on Cost and Value in Cancer Care.
Saltz LB
JAMA Oncol; 2016 Jan; 2(1):19-21. PubMed ID: 26501848
[No Abstract] [Full Text] [Related]
10. American Society of Clinical Oncology Position Statement on Addressing the Affordability of Cancer Drugs.
American Society of Clinical Oncology
J Oncol Pract; 2018 Mar; 14(3):187-192. PubMed ID: 29091534
[No Abstract] [Full Text] [Related]
11. Economic burden of cancer across the European Union: a population-based cost analysis.
Luengo-Fernandez R; Leal J; Gray A; Sullivan R
Lancet Oncol; 2013 Nov; 14(12):1165-74. PubMed ID: 24131614
[TBL] [Abstract][Full Text] [Related]
12. Minimalism in oncology.
The Lancet Oncology
Lancet Oncol; 2018 May; 19(5):579. PubMed ID: 29726372
[No Abstract] [Full Text] [Related]
13. United healthcare, five oncology practices try bundled payments.
Goozner M
J Natl Cancer Inst; 2011 Jan; 103(1):8-10. PubMed ID: 21169535
[No Abstract] [Full Text] [Related]
14. Bending the cost curve in cancer care.
Field K; Faragher I; Gibbs P
N Engl J Med; 2011 Aug; 365(7):675; author reply 675-6. PubMed ID: 21848477
[No Abstract] [Full Text] [Related]
15. US Cancer Care System Ill-Equipped to Deliver New Advances to Patients.
Rappaport M
J Oncol Pract; 2016 May; 12(5):397. PubMed ID: 27170686
[No Abstract] [Full Text] [Related]
16. Cancer care value-learning from others.
Gamble RB
Am J Manag Care; 2012 May; 18(3 Spec No.):SP139. PubMed ID: 22642284
[No Abstract] [Full Text] [Related]
17. Targeted immunotherapies overtaking emerging oncology market value based growth.
Jakovljevic MB
J BUON; 2015; 20(1):350-1. PubMed ID: 25778340
[No Abstract] [Full Text] [Related]
18. Value in Oncology: It Is in the Eyes of the Beholder.
Nabhan C; Phillips EG; Feinberg BA
J Natl Compr Canc Netw; 2019 Jan; 17(1):2-5. PubMed ID: 30659123
[No Abstract] [Full Text] [Related]
19. [Economic burden of cancer patients undergoing oral chemotherapy].
Koinuma N
Gan To Kagaku Ryoho; 2010 Jul; 37(7):1230-3. PubMed ID: 20647704
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness, cancer burden and financial crisis: a perfect storm.
Belda-Iniesta C
Clin Transl Oncol; 2012 Oct; 14(10):713-4. PubMed ID: 22996423
[No Abstract] [Full Text] [Related]
[Next] [New Search]
